Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06969534RecruitingPhase 2
Pucotenlimab for children with LECC cancer
This trial tests a new immunotherapy drug, pucotenlimab, for children and teens with a rare cancer called lymphoepithelioma-like carcinoma (LECC). The goal is to see if the drug is safe and helps shrink tumors.
Guangzhou, GuangdongAges 1–18 - NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06969729Recruiting
3D-printed aortic stent graft trial for aneurysms
This trial tests a custom-made aortic stent graft created with 3D printing technology for people with certain types of abdominal or thoracoabdominal aortic aneurysms. It aims to see if this new device is safe and works well to repair the aneurysm.
Szczecin, West Pomeranian VoivodeshipAges 18 years+ - NCT06970145RecruitingPhase 1/Phase 2
Anlotinib for recurrent craniopharyngioma
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
Guangzhou, GuangdongAges 18–75 - NCT06971094RecruitingPhase 3
Gene therapy for type 2 spinal muscular atrophy
This trial tests a new gene therapy called GC101 given as a one-time injection into the spinal fluid for people with type 2 spinal muscular atrophy (SMA). It may help improve motor function.
BeijingAges 2–12 - NCT06972732RecruitingPhase 4
Comparing three diabetes drugs for type 2 diabetes
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
Seoul, Seocho DistrictAges 19 years+ - NCT06974851RecruitingPhase 3
Study of HRS9531 for sleep apnea and obesity
This trial tests an injectable medication (HRS9531) to see if it helps people with both obstructive sleep apnea and obesity. It compares the drug to a placebo (no active medicine) to check safety and effectiveness.
Beijing, Beijing MunicipalityAges 18–75 - NCT06975722RecruitingPhase 2
Study of SAR442970 for Ulcerative Colitis
This trial tests a new drug called SAR442970 for adults with moderate to severe ulcerative colitis (UC) that has not responded well to standard treatments or other advanced therapies. The goal is to see if it can reduce symptoms and improve quality of life.
Escondido, CaliforniaAges 18–75 - NCT06975865RecruitingPhase 3
Rilzabrutinib for sickle-cell disease pain episodes
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
Birmingham, AlabamaAges 10–65 - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Fullerton, CaliforniaAges 60–85 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT06976671RecruitingPhase 2
Testing bevacizumab injection for frozen shoulder
This trial tests an injection of bevacizumab into the shoulder joint for people with frozen shoulder (adhesive capsulitis). The goal is to see if it can reduce pain and stiffness.
North Ryde, New South WalesAges 18 years+ - NCT06978699RecruitingPhase 2
Testing XH-S003 for people with PNH
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
TianjinAges 18 years+ - NCT06978725RecruitingPhase 2
Brepocitinib for skin sarcoidosis
This trial tests an oral medication called brepocitinib for people with sarcoidosis that affects the skin. It aims to see if the drug can safely reduce skin lesions and improve symptoms.
San Francisco, CaliforniaAges 18–75 - NCT06979271Recruiting
Testing a new drug combo for tough rheumatoid arthritis
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
Hangzhou, ZhejiangAges 18–85 - NCT06979752Recruiting
Testing a new cannula for glaucoma-cataract surgery
This trial tests whether a special cannula can help protect the eye during combined surgery for pseudoexfoliative glaucoma (a type of glaucoma with flaky deposits) and cataracts. It may offer better results than standard irrigation.
AvranchesAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT06981325RecruitingPhase 2
Cemiplimab for advanced basal cell carcinoma
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
ErfurtAges 18 years+ - NCT06983951Recruiting
Study of CAR T cells for light chain amyloidosis
This trial tests a type of immunotherapy called CAR T cells that target a protein called BCMA on abnormal cells. It is for people whose light chain amyloidosis has come back or not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06983964Recruiting
CAR-T cell therapy for autoimmune diseases that haven't improved
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
Beijing, Beijing MunicipalityAges 18–65 - NCT06984731Recruiting
Same-day ablation and WATCHMAN closure for AFib
This study tests whether doing a common AFib procedure (radiofrequency ablation) is safe and effective at the same time as closing off the left atrial appendage with the WATCHMAN FLX device. It's for people with nonvalvular atrial fibrillation who are already candidates for both treatments.
Nantong, JiangsuAges 18–80 - NCT06986174RecruitingPhase 2
Pacritinib for relapsed or refractory Waldenström macroglobulinemia
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
Boston, MassachusettsAges 18 years+ - NCT06987916RecruitingPhase 1/Phase 2
Testing new immune cell therapy for B-cell lymphoma
This trial tests a new immune cell treatment (called U01 or ssCART-19) for people with B-cell lymphoma that has come back or not responded to other treatments. It aims to see if the therapy is safe and effective.
Shanghai, Shanghai MunicipalityAges 2–75 - NCT06989892Recruiting
Comparing two dialysis filters for sepsis patients
This trial tests whether a newer, higher-performing dialysis filter helps people with kidney failure and sepsis better than the standard filter. It focuses on patients with high levels of inflammation (measured by a marker called interleukin-6).
Dusit, BangkokAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.